Surgeon reports high patient satisfaction with hydrogel corneal inlay
06 May 2014
Overall patient satisfaction is 98% after implantation with the Raindrop inlay, according to a surgeon here.
Domain Associates Unfazed By Biotech IPO Ups and Downs
10 April 2014
Biotechnology stocks have had a rollercoaster experience on the public markets this year, with the sector taking a major hit in recent weeks after a long run-up.
SIFI and NovaMedica link up to market eye care products in Russia
27 March 2014
Italian developer of innovative eye care solutions SIFI SpA Russian pharmaceutical company NovaMedica have entered into an exclusive commercial agreement for NovaMedica to market eight products developed and licensed by SIFI for the treatment of a wide range of ophthalmic pathologies in Russia and the CIS. Financial terms of the collaboration were not disclosed.
NovaMedica and Skolkovo Foundation to build a research centre
05 February 2014
NovaMedica's (Russia) research unit, NovaMedica Innotech, has entered into an agreement with Russian agency Skolkovo Foundation for the creation of research centre at technopark Skolkovo. According to the report by news website Pharmvestnik, the research centre is to include biochemical, analytical, and pharmaceutical laboratories with an experimental production of dosage forms.
The Last Word: Place Your Biotech Bets on Solid Management and Hot Therapy Areas
24 January 2014
Who got the last word at the 2014 Biotech Showcase? A portfolio manager specializing in healthcare, an award-winning analyst, and a pair of venture capitalists with global viewpoints and a focus on clinical-stage companies. In the closing event of the showcase, cohosted by The Life Sciences Report, this panel of experts offered insights into trends that will influence the biotech universe in 2014.
Nuvo Research und NovaMedica unterzeichnen Vereinbarung über Vermarktung von Pennsaid in Russland
20 December 2013
Nuvo Research Inc. (TSX: NRI), ein Spezial-Pharmaunternehmen mit einem vielfältigen Produktportfolio für die Bereiche topische Schmerzmittel und Immunologie, und NovaMedica LLC (NovaMedica), ein russisches Pharmaunternehmen, gaben heute bekannt, dass sie eine Liefer- und Vertriebsvereinbarung unterzeichnet haben, mit der NovaMedica die exklusiven Rechte auf Vermarktung und Vertrieb der Nuvo-Produkte Pennsaid 1,5% und Pennsaid 2% in Russland und einigen GUS-Staaten erhält.
Nuvo Research et NovaMedica signent un accord pour commercialiser Pennsaid en Russie
20 December 2013
Nuvo Research Inc. (TSX : NRI), une société spécialisée dans les produits pharmaceutiques possédant un portefeuille varié de produits dans les traitements topiques contre la douleur et l'immunologie, et NovaMedica LLC (NovaMedica), une société pharmaceutique russe, ont annoncé aujourd'hui qu'elles ont signé un accord de fourniture et de distribution qui permet à NovaMedica de bénéficier des droits exclusifs de commercialisation et de vente des produits Pennsaid 1,5 % et Pennsaid 2 % de Nuvo en Russie et dans certains pays de la Communauté des États indépendants (CEI).
Nuvo licenses Pennsaid in parts of CIS to NovaMedica
20 December 2013
Nuvo Research Inc. and NovaMedica LLC, a Russian pharmaceutical company, have signed a supply and distribution agreement providing NovaMedica the exclusive rights to market and sell Nuvo's Pennsaid 1.5 per cent and Pennsaid 2 per cent products in Russia and some of the Commonwealth of Independent States.
Nuvo Research® and NovaMedica sign agreement to market Pennsaid® in Russia
19 December 2013
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology, and NovaMedica LLC (NovaMedica), a Russian pharmaceutical company, today announced that they have signed a supply and distribution agreement providing NovaMedica the exclusive rights to market and sell Nuvo's Pennsaid 1.5% and Pennsaid 2% products in Russia and some of the Community of Independent States (CIS).
12 December 2013
NovaMedica LLC, ein russisches Pharmaunternehmen, und Venter Pharma SL, ein spanisches Unternehmen, das innovative diagnostische Systeme entwickelt, haben eine Partnerschaftsvereinbarung unterzeichnet, im Rahmen derer NovaMedica die Exklusivrechte erhält, um LacTEST®, eine neue Technologie für die Diagnose von Laktose-Intoleranz in Russland und der GUS (Gemeinschaft unabhängiger Staaten) zu vermarkten.
05 November 2024
03 November 2024
October 10 – World Mental Health Day
10 October 2024
Siberian State Medical University and Skoltech to start production of bone tissue fillers
22 November 2024
Sechenov University is creating a digital drug reference book
21 November 2024
Skills shortage still holding back pharma's digital transformation: survey
21 November 2024
Trials for Russia’s first CAR-T drug “Utzhefra” have started
20 November 2024